Marjaana Koponen
Yliopistonlehtori
Farmasian laitos, Terveystieteiden tiedekunta
marjaana.koponen@uef.fi | 040 355 3773
Julkaisut
85/85 kappaletta-
Cross-Regional Data Initiative for the Assessment and Development of Treatment for Neurological and Mental Disorders
Tsai, Daniel Hsiang Te; Bell, J. Simon; Abtahi, Shahab; Baak, Brenda N.; Bazelier, Marloes T; Brauer, Ruth; Chan, Adrienne YL; Chan, Esther W; Chen, Haoqian; Chui, Celine SL; Cook, Sharon; Crystal, Stephen; Gandhi, Poonam; Hartikainen, Sirpa; Ho, Frederick K; Hsu, Shao Ti; Ilomäki, Jenni; Kim, Ju Hwan; Klungel, Olaf H; Koponen, Marjaana; Lau, Wallis CY; Lau, Kui Kai; Lum, Terry YS; Luo, Hao; Man, Kenneth KC; Pell, Jill P; Setoguchi, Soko; Shao, Shih Chieh; Shen, Chin Yao; Shin, Ju Young; Souvere. 2023. Clinical epidemiology. 15: 1241-1252 -
Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
Puranen, Arto; Koponen, Marjaana; Lähteenvuo, Markku; Tanskanen, Antti; Tiihonen, Jari; Taipale, Heidi. 2023. Schizophrenia. 9: -
Recent Hospitalization and Initiation of Antiepileptics Among Persons With Alzheimer’s Disease
Elo, Jenna; Tolppanen, Anna-Maija; Koponen, Marjaana; Tiihonen, Miia; Hartikainen, Sirpa. 2023. Journal of the american medical directors association. 24: 213-219.e6 -
The Cumulative Use of Muscle Relaxants and the Risk of Alzheimer’s Disease: A Nationwide Case-Control Study
Rahkonen, Atte; Taipale, Heidi; Koponen, Marjaana; Hartikainen, Sirpa; Tolppanen, Anna-Maija; Tanskanen, Antti; Tiihonen, Miia. 2023. Journal of Alzheimer's disease. 91: 1283-1290 -
β2-Adrenoceptor Agonists in Asthma or Chronic Obstructive Pulmonary Disease and Risk of Parkinson’s Disease: Nested Case-Control Study
Paakinaho, Anne; Tiihonen, Miia; Koskela, Heikki; Koponen, Marjaana; Tiihonen, Jari; Hartikainen, Sirpa; Tolppanen, Anna-Maija. 2023. Clinical epidemiology. 15: 695-705 -
Antipsychotic Use and Risk of Stroke Among Community-Dwelling People With Alzheimer's Disease
Koponen, Marjaana; Rajamaki, Blair; Lavikainen, Piia; Bell, J Simon; Taipale, Heidi; Tanskanen, Antti; Hartikainen, Sirpa; Tolppanen, Anna-Maija. 2022. Journal of the american medical directors association. 23: 1059-1065 -
Association between different diabetes medication classes and risk of Parkinson's disease in people with diabetes
Sunnarborg, Katriina; Tiihonen, Miia; Huovinen, Marjo; Koponen, Marjaana; Hartikainen, Sirpa; Tolppanen, Anna‐Maija. 2022. Pharmacoepidemiology and drug safety. 31: 875-882 -
Disease-Modifying Antirheumatic Drugs and Risk of Parkinson Disease
Paakinaho, Anne; Koponen, Marjaana; Tiihonen, Miia; Kauppi, Markku; Hartikainen, Sirpa; Tolppanen, Anna-Maija. 2022. Neurology. 98: e1273-e1281 -
Identification of Drugs Associated with Lower Risk of Parkinson’s Disease Using a Systematic Screening Approach in a Nationwide Nested Case–Control Study
Koponen, Marjaana; Paakinaho, Anne; Lin, Julian; Hartikainen, Sirpa; Tolppanen, Anna-Maija. 2022. Clinical epidemiology. 14: 1217-1227 -
Incidence of antipsychotic use among community dwellers with and without Parkinson's disease
Lilja, Satu; Tolppanen, Anna-Maija; Koponen, Marjaana; Hartikainen, Sirpa; Tiihonen, Miia. 2022. Parkinsonism and related disorders. 103: 69-72